Sanofi snaps up acne vaccine developer Origimm Bio
pharmaphorum
DECEMBER 1, 2021
Sanofi said it would also apply its mRNA vaccine platform – acquired along with Translate Bio earlier this year – to find other acne vaccine candidates that could start clinical trials in 2023. Origimm’s expertise in the skin microbiome and antigen discovery will be central to that effort, it added.
Let's personalize your content